Vevo Therapeutics Plans to Open Source 100M Single-Cell Atlas for Drug Discovery
Vevo Therapeutics has announced plans to open source its Tahoe-100M dataset, described as the world's largest single-cell transcriptomic atlas of …
All Posts
Bioptimus Reaches $76M Milestone as It Prepares for Next-Gen AI Foundation Model
Bioptimus, a French AI startup, has announced a $76 million funding milestone, with $41 million secured in its latest round …
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
AbCellera has announced an expansion of its collaboration with AbbVie to include the development of T-cell engagers (TCEs) for oncology, …
AbbVie Partners with Simcere on T-Cell Engager for Multiple Myeloma in $1B Deal
AbbVie has partnered with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical, to advance a trispecific antibody candidate, SIM0500, for relapsed …
Truveta Raises $320M to Sequence 10M Exomes and Build Largest Genetic Database
The health data company Truveta, in collaboration with Regeneron and Illumina, and 17 major U.S. health systems, has launched the …
Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases
Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory …
Bayer's Cell Therapy for Replacing Dopamine Neurons in Parkinson’s Advances to Phase III
Bayer, through its subsidiary BlueRock Therapeutics, has announced plans to advance bemdaneprocel (BRT-DA01), its investigational pluripotent stem cell-derived dopaminergic neuron therapy …
Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation
Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including …
Sana Reports Promising Results for Type 1 Diabetes Islet Cell Transplants Without Immunosuppression
Sana Biotechnology announced promising early results from a first-in-human study of its hypoimmune (HIP) technology for type 1 diabetes. Conducted …
Verdiva Bio Launches With $411M to Propel Weekly-Dosed GLP-1 Obesity Drug
Verdiva Bio has launched with $411 million in Series A financing, reportedly one of the largest early-stage funding rounds for …
Insilico Medicine Licenses Second AI-Generated Cancer Drug Candidate in a $550M Deal
Insilico Medicine and Menarini Group’s Stemline Therapeutics have announced a second exclusive licensing agreement for an AI-discovered oncology drug candidate. …
Eli Lilly Partners with UK’s Alchemab to Develop New ALS Antibodies
Eli Lilly has partnered with UK-based biotech Alchemab Therapeutics to develop therapeutic antibodies targeting amyotrophic lateral sclerosis (ALS), a neurodegenerative …